CUSABIO) CD73 Protein Receives Great Attention in Researchers
작성자
abbabio
작성일자
2021-02-26
조회수
191
If you are unable to see the message below, click here to view.
On October 27, 2020, Akeso, Inc. announced the completion of its first clinical trial in New Zealand for its innovative drug candidate CD73 monoclonal antibody named AK119, which is intended to be used to treat patients with SARS-CoV-2 (COVID-19). CD73, also known as Ecto-5'-Nucleotidase, is an emerging tumor immune target, which is closely related to the occurrence, development, metastasis, and poor prognosis of tumors. Interesting reading of CD73…
Recently, CUSABIO has developed a recombinant human CD73 protein. Recombinant Human CD73 (CSB-MP723415HU) is expressed with a C-terminal 6xHis-tagged in Mammalian cell. Its purity was determined by SDS-PAGE and reached up to 95%. It was validated to be biologically active through functional ELISA analyses. This recombinant CD73 in-stock are available.
Purity>95%
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Activity
Measured by its binding ability in a functional ELISA. Immobilized CD73 at 2 μg/ml can bind Anti- CD73 Rabbit Monoclonal Antibody (CSB-RA978310A0HU), the EC50 is 3.212-4.525 ng/ml.
